CLRB

Cellectar Biosciences, Inc. [CLRB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CLRB Stock Summary

Top 10 Correlated ETFs

CLRB


Top 10 Correlated Stocks

CLRB


In the News

12:27 29 Mar 2024 CLRB

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript

06:40 29 Mar 2024 CLRB

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report its financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:

08:52 29 Mar 2024 CLRB

Cellectar Biosciences to Present at the 36th Annual Roth Conference

FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jim Caruso, president and chief executive officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming 36th Annual Roth Conference taking place on March 17 to 19, 2024 in Laguna Niguel, CA. Details of the fireside chat are as follows:

01:34 29 Mar 2024 CLRB

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Cellectar Biosciences is a developmental biotech focused on a radiolabeled phospholipid for hematologic malignancies, with a focus on Waldenstrom's macroglobulinemia. Their most advanced development is in Waldenstrom's, with positive trial results and plans to file for Accelerated Approval. The company has a strong chance at approval but faces cash concerns and the challenge of a small market size for its drug.

06:40 29 Mar 2024 CLRB

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and chief executive officer of Cellectar, will present an overview of the company at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually. Details of the presentation are as follows:

08:37 29 Mar 2024 CLRB

Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?

Cellectar Biosciences (NASDAQ: CLRB ) stock is heading higher on Monday after the company posted positive results from its CLOVER WaM study of iopofosine I 131. According to a press release from the company, iopofosine I 131 performed well in the trial as a potential first-in-class, targeted radiotherapy candidate to treat patients with relapsed/refractory Waldenstrom's macroglobulinemia that have already undergone a minimum of two previous forms of therapy.

06:41 29 Mar 2024 CLRB

Cellectar's blood cancer therapy succeeds in trial

Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines of therapy.

08:30 29 Mar 2024 CLRB

Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe

FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, Cellectar's chief operating officer (COO), will deliver a presentation and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe, being held December 5-7, 2023 in Berlin, Germany.

02:19 29 Mar 2024 CLRB

Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript

Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors James Caruso - CEO Chad Kolean - CFO Shane Lea - CCO Andrei Shustov - SVP, Medical Conference Call Participants Jonathan Aschoff - ROTH MKM Jeffrey Jones - Oppenheimer Ahu Demir - Ladenburg Jason McCarthy - Maxim Group Operator Good morning, and welcome to Cellectar Biosciences Third Quarter 2023 Update Call. Today's conference is being recorded.

01:32 29 Mar 2024 CLRB

Here's Why Cellectar Biosciences Shares Are Rising

Cellectar Biosciences Inc (NASDAQ: CLRB) shares are trading higher by 12.1% at $0.61 after the company reported better-than-expected fourth-quarter EPS results. Cellectar Biosciences beat estimated earnings by 10.0%, reporting an EPS loss of 9 cents versus an estimate of a.

CLRB Financial details

Company Rating
Sell
Market Cap
49.77M
Income
-37.63M
Revenue
0
Book val./share
-1.18
Cash/share
1.68
Dividend
-
Dividend %
-
Employees
15
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-1.1
Forward P/E
-8.12
PEG
0.78
P/S
-
P/B
-3.09
P/C
2.37
P/FCF
-1.45
Quick Ratio
1.15
Current Ratio
1.22
Debt / Equity
-0.04
LT Debt / Equity
-0.04
-
-
EPS (TTM)
-3.71
EPS next Y
-0.49
EPS next Q
-0.53
EPS this Y
-6.25%
EPS next Y
-86.7%
EPS next 5Y
-132.75%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
65.75%
-
-
-
-
SMA20
-
SMA50
-
SMA100
100%
Inst Own
0%
Inst Trans
1%
ROA
-175%
ROE
-1668%
ROC
-6.66%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
12.29M
Shs Float
11.13M
-
-
-
-
Target Price
-
52W Range
1.3-4.45
52W High
-0.5%
52W Low
+298%
RSI
58
Rel Volume
0.96
Avg Volume
1.84M
Volume
1.76M
Perf Week
2.84%
Perf Month
15.36%
Perf Quarter
43.68%
Perf Half Y
60.48%
-
-
-
-
Beta
0.93
-
-
Volatility
0.13%, 0.28%
Prev Close
0%
Price
3.98
Change
3.65%

CLRB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-44.7-18.08-7.45-4.32-4.05
Operating cash flow per share
-38.63-15.24-7.03-4.07-3.57
Free cash flow per share
-39.93-15.27-7.06-4.09-3.61
Cash per share
44.7513.8328.856.432.82
Book value per share
44.7711.827.665.952.2
Tangible book value per share
44.7711.827.665.952.2
Share holders equity per share
44.7711.827.665.952.2
Interest debt per share
0.110.690.210.050.04
Market cap
4.59M17.27M41.21M36.64M12.07M
Enterprise value
-8.66M7.18M-15.53M1.24M-7.2M
P/E ratio
-0.35-1.24-2.79-1.53-0.42
Price to sales ratio
00000
POCF ratio
-0.4-1.48-2.96-1.62-0.48
PFCF ratio
-0.39-1.47-2.94-1.61-0.47
P/B Ratio
0.351.910.751.110.78
PTB ratio
0.351.910.751.110.78
EV to sales
00000
Enterprise value over EBITDA
0.87-0.51-0.050.25
EV to operating cash flow
0.76-0.611.11-0.050.29
EV to free cash flow
0.73-0.611.11-0.050.28
Earnings yield
-2.88-0.8-0.36-0.65-2.37
Free cash flow yield
-2.58-0.68-0.34-0.62-2.11
Debt to equity
00.060.010.010.04
Debt to assets
00.040.010.010.03
Net debt to EBITDA
1.330.713.671.470.67
Current ratio
8.64.1116.269.163.71
Interest coverage
-449.0400095.74
Income quality
0.860.830.920.940.88
Dividend Yield
0.490000
Payout ratio
-0.170000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.03000.010.01
Capex to revenue
00000
Capex to depreciation
-4.68-0.18-0.44-0.94-1.52
Stock based compensation to revenue
00000
Graham number
212.1969.2968.0824.0514.16
ROIC
-0.89-1.38-0.27-0.71-1.72
Return on tangible assets
-0.88-1.13-0.25-0.64-1.32
Graham Net
38.79.6726.95.681.95
Working capital
12.33M8.62M54.38M32.58M15M
Tangible asset value
13.26M9.06M54.79M33.05M15.51M
Net current asset value
12.16M8.19M54.07M32.41M14.45M
Invested capital
00.060.010.010.04
Average receivables
00000
Average payables
306K945K1.35M1.42M1.99M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
02.46K2.51K2.27K3.91K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00.150.150.160.09
Inventory turnover
00000
ROE
-1-1.53-0.27-0.73-1.84
Capex per share
-1.3-0.03-0.03-0.03-0.03

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.28-1.02-0.75-0.73-1.21
Operating cash flow per share
-1.15-1.05-0.64-0.67-0.71
Free cash flow per share
-1.15-1.07-0.64-0.67-0.77
Cash per share
2.912.821.130.461.68
Book value per share
2.092.20.65-0.04-1.18
Tangible book value per share
2.092.20.65-0.04-1.18
Share holders equity per share
2.092.20.65-0.04-1.18
Interest debt per share
0.030.080.040.050.05
Market cap
20.53M12.07M16.1M21.96M29.86M
Enterprise value
2.95M-7.2M4.02M17.39M11.44M
P/E ratio
-0.66-0.42-0.48-0.67-0.54
Price to sales ratio
00000
POCF ratio
-2.93-1.63-2.24-2.92-3.7
PFCF ratio
-2.92-1.6-2.24-2.92-3.45
P/B Ratio
1.610.782.2-47.02-2.24
PTB ratio
1.610.782.2-47.02-2.24
EV to sales
00000
Enterprise value over EBITDA
-0.380.97-0.46-2.11-1.22
EV to operating cash flow
-0.420.97-0.56-2.31-1.42
EV to free cash flow
-0.420.96-0.56-2.31-1.32
Earnings yield
-0.38-0.6-0.53-0.37-0.46
Free cash flow yield
-0.34-0.62-0.45-0.34-0.29
Debt to equity
0.020.040.08-1.25-0.04
Debt to assets
0.010.030.040.090.03
Net debt to EBITDA
2.262.61.390.551.96
Current ratio
2.883.711.990.871.22
Interest coverage
-1.88K1.46K70.1800
Income quality
0.91.030.840.920.59
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.02000.07
Capex to revenue
00000
Capex to depreciation
-0.21-3.0900-14.49
Stock based compensation to revenue
00000
Graham number
7.757.113.320.835.68
ROIC
-0.59-0.44-1.01-11.820.77
Return on tangible assets
-0.4-0.33-0.57-1.26-0.64
Graham Net
1.841.950.46-0.16-1.41
Working capital
12.25M15M6.89M-835.66K3.64M
Tangible asset value
12.75M15.51M7.33M-467K-13.35M
Net current asset value
12.19M14.45M6.34M-1.37M-14.79M
Invested capital
0.020.040.08-1.25-0.04
Average receivables
00000
Average payables
3.18M4.46M4.73M6.65M7.1M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
10.24K3.71K11.02K10.88K12.57K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.010.020.010.010.01
Inventory turnover
00000
ROE
-0.61-0.47-1.1517.61.03
Capex per share
0-0.0200-0.05

CLRB Frequently Asked Questions

What is Cellectar Biosciences, Inc. stock symbol ?

Cellectar Biosciences, Inc. is a US stock , located in Florham park of Nj and trading under the symbol CLRB

What is Cellectar Biosciences, Inc. stock quote today ?

Cellectar Biosciences, Inc. stock price is $3.98 today.

Is Cellectar Biosciences, Inc. stock public?

Yes, Cellectar Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap